🇪🇺 Qulipta in European Union

EMA authorised Qulipta on 11 August 2023

Marketing authorisation

EMA — authorised 11 August 2023

  • Application: EMEA/H/C/005871
  • Marketing authorisation holder: AbbVie Deutschland GmbH & Co. KG
  • Local brand name: Aquipta
  • Indication: Aquipta is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month
  • Status: approved

Read official source →

Qulipta in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Neuroscience approved in European Union

Frequently asked questions

Is Qulipta approved in European Union?

Yes. EMA authorised it on 11 August 2023.

Who is the marketing authorisation holder for Qulipta in European Union?

AbbVie Deutschland GmbH & Co. KG holds the EU marketing authorisation.